(Total Views: 602)
Posted On: 02/06/2023 10:01:07 PM
Post# of 154851
BioSpace Oct/31/2022:
"The other two issues are expected to be turned over to the FDA in the next few months" Arman said.
He also said he "was aware of the issues with the CRO prior to joining Cytodyn, but, that the potential of the drug... is what drew him to the company in the first place."
What is considered to be a few months???...a FEW is normally between 3-5 months...we just came into the range.
"The other two issues are expected to be turned over to the FDA in the next few months" Arman said.
He also said he "was aware of the issues with the CRO prior to joining Cytodyn, but, that the potential of the drug... is what drew him to the company in the first place."
What is considered to be a few months???...a FEW is normally between 3-5 months...we just came into the range.
(2)
(0)
